Published in TB and Outbreaks Week, November 15th, 1999
But the U.S. Food and Drug Administration (FDA) said there is no need for panic: intravenous penicillin G is the preferred therapy for only a handful of rare infections. Even for those, other types of penicillin or newer antibiotics are successful treatments.
The shortage began in June 1999, when Marsam Pharmaceuticals recalled its IV penicillin G supplies and quit manufacturing. An FDA inspection had cited serious manufacturing deficiencies that it said raised questions about the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.